Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With Gemcitabine/Docetaxel Followed by Doxorubicin: A Phase II Trial
Brief Summary: The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy). The major objective of this study is to determine the progression free survival. The goal is to prevent relapse or recurrence of their uterine leiomyosarcoma.


Options:
A: Arm Label: gemcitabine/docetaxel then doxorubicin; Type: OTHER; Interventions: Drug: gemcitabine, docetaxel, doxorubicin | Intervention Type: DRUG; Name: gemcitabine, docetaxel, doxorubicin; Assigned to Arm(s): gemcitabine/docetaxel then doxorubicin
B: Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: isolated perfusion; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
C: Arm Label: Regimen A; Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: adjuvant therapy, Procedure: conventional surgery, Procedure: neoadjuvant therapy, Radiation: brachytherapy, Radiation: radiation therapy | Arm Label: Regimen B; Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: adjuvant therapy, Procedure: conventional surgery, Procedure: neoadjuvant therapy, Radiation: brachytherapy, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: RADIATION; Name: brachytherapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Regimen A, Regimen B
D: Arm Label: sorafenib and everolimus; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib, Drug: Everolimus | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): sorafenib and everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): sorafenib and everolimus

Answer: A